On May, 8 Horizon Pharma plc (HZNP) Analysts See $0.11 EPS

Horizon Pharma plc (NASDAQ:HZNP) Corporate Logo
Big Money Sentiment increased to 1.33 in 2018 Q4. It has change of 0.47, from 2018Q3’s 0.86. The ratio improved due to Horizon Pharma plc positioning: 27 sold and 60 reduced. 54 funds bought stakes and 62 increased stakes. Investors holded 134.96 million in 2018Q3 but now own 136.51 million shares or 1.16% more.
Proxima Lc accumulated 55,000 shs or 1.02% of the stock. State Board Of Administration Of Florida Retirement, Florida-based fund reported 160,045 shs. The Illinois-based Northern has invested 0.01% in Horizon Pharma plc (NASDAQ:HZNP). Panagora Asset Mngmt invested in 0.11% or 1.17M shs. Moreover, Us Retail Bank De has 0% invested in Horizon Pharma plc (NASDAQ:HZNP). Dekabank Deutsche Girozentrale accumulated 52,000 shs. Element Cap Management Limited Liability Corporation stated it has 20,005 shs or 0.01% of all its holdings. Eaton Vance stated it has 0% in Horizon Pharma plc (NASDAQ:HZNP). Legal General Public Limited Co holds 73,686 shs. Moreover, Malaga Cove Capital Ltd Company has 0.66% invested in Horizon Pharma plc (NASDAQ:HZNP). Redwood Invs Ltd Liability Co has invested 1.95% of its capital in Horizon Pharma plc (NASDAQ:HZNP). Voloridge Mngmt Ltd Limited Liability Company accumulated 0.05% or 55,652 shs. Moreover, Maverick has 0.08% invested in Horizon Pharma plc (NASDAQ:HZNP) for 285,100 shs. Zurcher Kantonalbank (Zurich Cantonalbank) has 12,271 shs for 0% of their capital. First Quadrant L P Ca reported 15,161 shs stake.

Horizon Pharma plc registered $9.00 million net activity with 0 insider buys and 2 selling transactions since November 14, 2018. Walbert Timothy P also sold $8.80M worth of Horizon Pharma plc (NASDAQ:HZNP) shs.

On May, 8. Investors wait Horizon Pharma plc (NASDAQ:HZNP) to report its quarterly earnings, RTT reports. Analysts predict $0.11 earnings per share. That’s $0.08 up or 266.67 % from 2018’s earnings of $0.03. If the current earnings per share of $0.11 is accurate, HZNP’s profit could hit $20.30M. After $0.67 EPS report previous quarter, Wall Street now sees -83.58 % negative EPS growth of Horizon Pharma plc. Ticker’s shares touched $24.6 during the last trading session after 4.02% change.Horizon Pharma plc has volume of 1.55M shares. Since April 18, 2018 HZNP has risen 89.51% and is uptrending. HZNP outperformed the S&P500 by 85.14%.

Horizon Pharma plc (NASDAQ:HZNP) Ratings Coverage

In total 5 analysts cover Horizon Pharma (NASDAQ:HZNP). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. 80% are bullish. 9 are the (NASDAQ:HZNP)’s analyst reports since November 15, 2018 according to StockzIntelligence Inc. On Monday, March 4 Morgan Stanley maintained Horizon Pharma plc (NASDAQ:HZNP) rating. Morgan Stanley has “Hold” rating and $32 target. On Wednesday, February 27 the firm has “Hold” rating by Mizuho given. On Wednesday, April 3 the rating was maintained by Cantor Fitzgerald with “Overweight”. In Thursday, November 15 report Mizuho downgraded it to “Neutral” rating and $21 target. On Friday, March 1 JMP Securities maintained the shares of HZNP in report with “Buy” rating. On Thursday, February 28 the firm earned “Buy” rating by Cowen & Co. On Thursday, February 28 the company was maintained by Jefferies. On Wednesday, February 27 Cantor Fitzgerald maintained the shares of HZNP in report with “Buy” rating.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.The firm is worth $4.54 billion. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout.Last it reported negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

For more Horizon Pharma plc (NASDAQ:HZNP) news released recently go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Horizon Pharma up 23% premarket on positive teprotumumab data – Seeking Alpha” released on February 28, 2019, “Horizon Pharma beats by $0.13, beats on revenue – Seeking Alpha” on February 27, 2019, “Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy – Nasdaq” with a publish date: January 02, 2019, “Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don’t? – Nasdaq” and the last “Why Is Horizon Pharma (HZNP) Down 9.9% Since Last Earnings Report? – Nasdaq” with publication date: March 29, 2019.

Horizon Pharma plc (NASDAQ:HZNP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.